{"id":20328,"date":"2023-10-03T17:21:56","date_gmt":"2023-10-03T15:21:56","guid":{"rendered":"https:\/\/ggba.swiss\/nagi-bioscience-secures-chf-12-4-million-to-propel-animal-alternative-testing\/"},"modified":"2023-10-03T17:25:57","modified_gmt":"2023-10-03T15:25:57","slug":"nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/","title":{"rendered":"Nagi Bioscience d\u00e9croche CHF 12.4 millions pour ses solutions alternatives \u00e0 l&rsquo;exp\u00e9rimentation animale"},"content":{"rendered":"\n<p><a href=\"https:\/\/nagibio.ch\/\">Nagi Bioscience<\/a>, une start-up sp\u00e9cialis\u00e9e dans les sciences de la vie, a cl\u00f4tur\u00e9 son cycle de financement de s\u00e9rie A avec un apport sursouscrit de CHF 12.4 millions, catapultant ainsi sa vision du d\u00e9veloppement d&rsquo;un \u00e9quipement de laboratoire r\u00e9volutionnaire qui ouvre la voie \u00e0 des solutions alternatives \u00e0 l&rsquo;exp\u00e9rimentation animale. Cet investissement substantiel provient de soci\u00e9t\u00e9s de capital-risque r\u00e9put\u00e9es \u00e0 travers l&rsquo;Europe, soulignant le potentiel illimit\u00e9 de l&rsquo;approche humaine et innovante de Nagi Bioscience en mati\u00e8re de d\u00e9couverte de m\u00e9dicaments et de tests toxicologiques.<\/p>\n\n\n\n<p>Pour son entr\u00e9e sur le march\u00e9, Nagi Bioscience a lanc\u00e9 <a href=\"https:\/\/nagibio.ch\/products-services\/sydlab-system\">SydLab One<\/a> \u00e0 la fin du premier trimestre 2023, s&rsquo;implantant notamment dans les secteurs de la biopharmacie et de la R&amp;D agrochimique. Matteo Cornaglia, CEO et cofondateur de Nagi Bioscience, a exprim\u00e9 sa gratitude envers les investisseurs en d\u00e9clarant : \u00ab&nbsp;Le soutien enthousiaste de nos nouveaux investisseurs refl\u00e8te notre conviction dans le potentiel de Nagi \u00e0 transformer les march\u00e9s de la d\u00e9couverte de m\u00e9dicaments et des tests de toxicologie. Cet investissement substantiel t\u00e9moigne du travail acharn\u00e9, du d\u00e9vouement et de la passion de notre incroyable \u00e9quipe et sera d\u00e9terminant pour la mise \u00e0 l&rsquo;\u00e9chelle de l&rsquo;organisation et des op\u00e9rations commerciales, tout en d\u00e9veloppant les activit\u00e9s de R&amp;D afin de renforcer le portefeuille de produits innovants de Nagi.&nbsp;\u00bb<\/p>\n\n\n\n<p>Le tour de financement est le fruit d&rsquo;une collaboration entre Swisscanto et imec.xpand, avec la participation d&rsquo;Excellis Holding, de Verve Ventures et de la Banque cantonale de Zurich. Les investisseurs partagent un enthousiasme collectif pour l&rsquo;approche r\u00e9volutionnaire de Nagi Bioscience, qui vise \u00e0 remplacer un large \u00e9ventail de tests sur les mammif\u00e8res dans diverses industries. Robert Schier, Senior Director de Swisscanto, souligne : \u00ab&nbsp;Nous sommes tr\u00e8s enthousiastes quant au potentiel de Nagi&#8230; L&rsquo;entreprise et sa technologie sont d&rsquo;excellents exemples de l&rsquo;innovation et de l&rsquo;esprit d&rsquo;entreprise suisses de grande qualit\u00e9.&nbsp;\u00bb<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Vers de nouveaux horizons<\/h4>\n\n\n\n<p>Les collaborations ont \u00e9t\u00e9 la pierre angulaire de la r\u00e9ussite de Nagi Bioscience, qui entretient des relations \u00e9troites avec ses clients afin de co-cr\u00e9er des solutions qui r\u00e9pondent v\u00e9ritablement aux besoins du march\u00e9. Frank Bulens, partenaire d&rsquo;imec.xpand, a soulign\u00e9 que \u00ab&nbsp;Nagi a introduit une nouvelle norme pour l&rsquo;\u00e9valuation pr\u00e9clinique, permettant d&rsquo;identifier des compos\u00e9s int\u00e9ressants plus rapidement et de mani\u00e8re plus rentable&nbsp;\u00bb.<\/p>\n\n\n\n<p>Cette lev\u00e9e de fonds de s\u00e9rie A permettra \u00e0 Nagi Bioscience d\u2019explorer de nouveaux march\u00e9s, forger des partenariats solides et bouleverser le paradigme des tests biologiques conventionnels.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nagi Bioscience a lev\u00e9 CHF 12.4 millions pour ouvrir la voie \u00e0 de nouveaux march\u00e9s et \u00e0 de nouvelles innovations, afin d&rsquo;acc\u00e9l\u00e9rer le mouvement vers des solutions de laboratoire sans cruaut\u00e9 de nouvelle g\u00e9n\u00e9ration.<\/p>\n","protected":false},"author":6,"featured_media":20324,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1210,1148,1171,1142],"class_list":["post-20328","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-diagnostic-fr-2","tag-financing-fr-2","tag-pharma-fr-2","tag-rd-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa<\/title>\n<meta name=\"description\" content=\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa\" \/>\n<meta property=\"og:description\" content=\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-03T15:21:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-03T15:25:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nagi Bioscience d\u00e9croche CHF 12.4 millions pour ses solutions alternatives \u00e0 l&rsquo;exp\u00e9rimentation animale\",\"datePublished\":\"2023-10-03T15:21:56+00:00\",\"dateModified\":\"2023-10-03T15:25:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\"},\"wordCount\":465,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Diagnostic\",\"Financing\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\",\"name\":\"Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"datePublished\":\"2023-10-03T15:21:56+00:00\",\"dateModified\":\"2023-10-03T15:25:57+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Nagi Bioscience est sur le point de red\u00e9finir le paysage des technologies de d\u00e9couverte de m\u00e9dicaments et de tests toxicologiques de nouvelle g\u00e9n\u00e9ration, en mettant des solutions d'essais sans exp\u00e9rimentation animale \u00e0 la port\u00e9e de la communaut\u00e9 scientifique mondiale. | @ Nagi Bioscience\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nagi Bioscience d\u00e9croche CHF 12.4 millions pour ses solutions alternatives \u00e0 l&#8217;exp\u00e9rimentation animale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa","description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/","og_locale":"fr_FR","og_type":"article","og_title":"Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa","og_description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","og_url":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-03T15:21:56+00:00","article_modified_time":"2023-10-03T15:25:57+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nagi Bioscience d\u00e9croche CHF 12.4 millions pour ses solutions alternatives \u00e0 l&rsquo;exp\u00e9rimentation animale","datePublished":"2023-10-03T15:21:56+00:00","dateModified":"2023-10-03T15:25:57+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/"},"wordCount":465,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","keywords":["Biotech","Diagnostic","Financing","Pharma","R&amp;D"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/","url":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/","name":"Nagi Bioscience d\u00e9croche CHF 12.4 millions | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","datePublished":"2023-10-03T15:21:56+00:00","dateModified":"2023-10-03T15:25:57+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Propelling the momentum towards humane, next-gen laboratory solutions, Nagi Bioscience has secured CHF 12.4 million.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Nagi-Bioscience-1180x811-1.png","width":1180,"height":811,"caption":"Nagi Bioscience est sur le point de red\u00e9finir le paysage des technologies de d\u00e9couverte de m\u00e9dicaments et de tests toxicologiques de nouvelle g\u00e9n\u00e9ration, en mettant des solutions d'essais sans exp\u00e9rimentation animale \u00e0 la port\u00e9e de la communaut\u00e9 scientifique mondiale. | @ Nagi Bioscience"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/nagi-bioscience-decroche-chf-12-4-millions-pour-ses-solutions-alternatives-a-lexperimentation-animale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Nagi Bioscience d\u00e9croche CHF 12.4 millions pour ses solutions alternatives \u00e0 l&#8217;exp\u00e9rimentation animale"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20328"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20328\/revisions"}],"predecessor-version":[{"id":20330,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20328\/revisions\/20330"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20324"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}